CN119285527A - 色胺前药 - Google Patents
色胺前药 Download PDFInfo
- Publication number
- CN119285527A CN119285527A CN202410898937.9A CN202410898937A CN119285527A CN 119285527 A CN119285527 A CN 119285527A CN 202410898937 A CN202410898937 A CN 202410898937A CN 119285527 A CN119285527 A CN 119285527A
- Authority
- CN
- China
- Prior art keywords
- linear
- alkyl
- compound
- branched
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063045901P | 2020-06-30 | 2020-06-30 | |
| US63/045,901 | 2020-06-30 | ||
| US202063109095P | 2020-11-03 | 2020-11-03 | |
| US63/109,095 | 2020-11-03 | ||
| CN202180046999.1A CN115867533B (zh) | 2020-06-30 | 2021-06-30 | 色胺前药 |
| PCT/CA2021/050907 WO2022000091A1 (en) | 2020-06-30 | 2021-06-30 | Tryptamine prodrugs |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180046999.1A Division CN115867533B (zh) | 2020-06-30 | 2021-06-30 | 色胺前药 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119285527A true CN119285527A (zh) | 2025-01-10 |
Family
ID=79032374
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410898937.9A Pending CN119285527A (zh) | 2020-06-30 | 2021-06-30 | 色胺前药 |
| CN202410898893.XA Pending CN119285526A (zh) | 2020-06-30 | 2021-06-30 | 色胺前药 |
| CN202180046999.1A Active CN115867533B (zh) | 2020-06-30 | 2021-06-30 | 色胺前药 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410898893.XA Pending CN119285526A (zh) | 2020-06-30 | 2021-06-30 | 色胺前药 |
| CN202180046999.1A Active CN115867533B (zh) | 2020-06-30 | 2021-06-30 | 色胺前药 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11292765B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4172145B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7702654B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102829078B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN119285527A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021302692A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181092A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK4172145T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI4172145T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL299506B2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT4172145T (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022016212A (cg-RX-API-DMAC7.html) |
| PT (1) | PT4172145T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022000091A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス, インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| AU2021215709A1 (en) | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| DK4172145T3 (da) * | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| WO2022040802A1 (en) * | 2020-08-26 | 2022-03-03 | Magicmed Industries Inc. | Glycosylated psilocybin derivatives and methods of using |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| EP4277894A1 (en) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| JP2024520832A (ja) | 2021-06-08 | 2024-05-24 | エンセオジェニックス バイオサイエンシズ, インコーポレイテッド | セロトニン受容体のジメトキシフェニルアルキルアミン活性化剤 |
| AU2022309017A1 (en) | 2021-07-07 | 2024-01-25 | Terran Biosciences Inc. | N,n-dimethyltryptamine and related psychedlics and uses thereof |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| KR20240065084A (ko) * | 2021-08-20 | 2024-05-14 | 테란 바이오사이언시스 인코포레이티드 | 사일로신의 전구약물 및 유도체 및 그의 용도 |
| WO2023086962A1 (en) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof |
| AU2022408191B2 (en) * | 2021-12-10 | 2025-05-15 | Caamtech, Inc. | Psilocybin derivatives |
| US20250051278A1 (en) * | 2021-12-14 | 2025-02-13 | Reunion Neuroscience, Inc. | Tryptamine prodrugs |
| CA3242479A1 (en) | 2021-12-27 | 2023-07-06 | Atai Therapeutics, Inc. | AMINOTERALINE SEROTONIN RECEPTOR ACTIVATORS |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023130075A2 (en) | 2021-12-31 | 2023-07-06 | Empyrean Neuroscience, Inc. | Genetically modified organisms for producing psychotropic alkaloids |
| US20250066299A1 (en) * | 2022-01-06 | 2025-02-27 | Terran Biosciences Inc. | Salts and solid forms of 4-hydroxy-n,n-diisopropyltryptamine hemi-glutarate and hemi-succinate |
| WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20250186369A1 (en) * | 2022-03-07 | 2025-06-12 | Drexel University | Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder |
| AU2023235712A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | C4-substituted tryptamine derivatives and methods of using |
| US12065404B2 (en) * | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| EP4493541A4 (en) * | 2022-03-18 | 2026-02-25 | Enveric Biosciences Canada Inc | TRYPTAMINE DERIVATIVES SUBSTITUTED BY C4-CARBOXYLIC ACID AND METHODS OF USE |
| AU2022447256A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | C4-carbonothioate-substituted tryptamine derivatives and methods of using |
| AU2023254841B2 (en) * | 2022-04-13 | 2025-10-23 | Caamtech, Inc. | Tryptamine derivatives |
| CN115521240B (zh) * | 2022-06-01 | 2024-05-28 | 杭州奥泰生物技术股份有限公司 | 一种二甲基色胺半抗原和人工抗原及其制备方法与应用 |
| AU2023313326A1 (en) * | 2022-07-27 | 2024-12-19 | Reconnect Labs Ag | Highly soluble formulations of harmine |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| CN116283885B (zh) * | 2022-12-01 | 2025-02-14 | 杭州奥泰生物技术股份有限公司 | 一种帕罗西汀半抗原和人工抗原及其制备方法与应用 |
| WO2024145719A1 (en) * | 2023-01-05 | 2024-07-11 | Reunion Neuroscience Inc. | Improved pharmacokinetics of tryptamine prodrugs |
| WO2024178051A2 (en) * | 2023-02-22 | 2024-08-29 | Caamtech, Inc. | Tryptamine derivatives |
| US12343319B2 (en) | 2023-05-01 | 2025-07-01 | Atai Therapeutics, Inc. | Compositions and methods for treatment of diseases and disorders |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2025099725A1 (en) * | 2023-11-09 | 2025-05-15 | Hadasit Medical Research Services And Development Ltd. | Conjugates and uses thereof |
| WO2025238416A1 (en) * | 2024-05-16 | 2025-11-20 | Mindset Pharma Inc. | Indole derivatives, uses and compositions thereof |
| WO2025250900A1 (en) * | 2024-05-30 | 2025-12-04 | Caamtech, Inc. | 4-hydroxy-n,n-diisopropyltryptaminium hydroglutarate |
| WO2026024591A1 (en) * | 2024-07-22 | 2026-01-29 | Reunion Neuroscience, Inc. | Tryptamine prodrug solid forms |
| WO2026128398A1 (en) * | 2024-12-09 | 2026-06-18 | Reunion Neuroscience, Inc. | Treatment of adjustment disorder |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| NL121067C (cg-RX-API-DMAC7.html) | 1958-09-12 | |||
| CH373381A (de) | 1959-07-13 | 1963-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer basischer Indol-Derivate |
| CH386422A (de) | 1960-03-30 | 1965-01-15 | Sandoz Ag | Verfahren zur Herstellung neuer Ester der Indol-Reihe |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| WO1995006638A1 (en) * | 1993-09-01 | 1995-03-09 | Allelix Biopharmaceuticals Inc. | Tryptamine analogs with 5-ht1d selectivity |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| WO2006047032A2 (en) | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| US8809261B2 (en) | 2008-10-31 | 2014-08-19 | Elsohly Laboratories, Incorporated | Compositions containing delta-9-THC-amino acid esters and process of preparation |
| US20180021326A1 (en) * | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| US12616706B2 (en) * | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| MX2022009527A (es) | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| DK4172145T3 (da) * | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
-
2021
- 2021-06-30 DK DK21832431.7T patent/DK4172145T3/da active
- 2021-06-30 CN CN202410898937.9A patent/CN119285527A/zh active Pending
- 2021-06-30 CA CA3181092A patent/CA3181092A1/en active Pending
- 2021-06-30 WO PCT/CA2021/050907 patent/WO2022000091A1/en not_active Ceased
- 2021-06-30 EP EP21832431.7A patent/EP4172145B1/en active Active
- 2021-06-30 AU AU2021302692A patent/AU2021302692A1/en active Pending
- 2021-06-30 FI FIEP21832431.7T patent/FI4172145T3/fi active
- 2021-06-30 KR KR1020237003292A patent/KR102829078B1/ko active Active
- 2021-06-30 KR KR1020257021837A patent/KR20250103811A/ko active Pending
- 2021-06-30 EP EP26177764.3A patent/EP4786000A2/en active Pending
- 2021-06-30 US US17/364,047 patent/US11292765B2/en active Active
- 2021-06-30 LT LTEPPCT/CA2021/050907T patent/LT4172145T/lt unknown
- 2021-06-30 CN CN202410898893.XA patent/CN119285526A/zh active Pending
- 2021-06-30 PT PT218324317T patent/PT4172145T/pt unknown
- 2021-06-30 JP JP2022580938A patent/JP7702654B2/ja active Active
- 2021-06-30 CN CN202180046999.1A patent/CN115867533B/zh active Active
- 2021-06-30 IL IL299506A patent/IL299506B2/en unknown
- 2021-06-30 MX MX2022016212A patent/MX2022016212A/es unknown
-
2022
- 2022-02-24 US US17/679,439 patent/US20220177427A1/en not_active Abandoned
-
2024
- 2024-09-30 US US18/902,773 patent/US20250129023A1/en active Pending
-
2025
- 2025-04-30 IL IL320601A patent/IL320601A/en unknown
- 2025-06-05 JP JP2025094025A patent/JP7864902B2/ja active Active
- 2025-08-22 US US19/308,120 patent/US20250382267A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102829078B1 (ko) | 2025-07-04 |
| IL320601A (en) | 2025-07-01 |
| CN115867533B (zh) | 2024-07-23 |
| EP4172145A1 (en) | 2023-05-03 |
| US20210403425A1 (en) | 2021-12-30 |
| IL299506B2 (en) | 2025-10-01 |
| JP7702654B2 (ja) | 2025-07-04 |
| IL299506A (en) | 2023-02-01 |
| IL299506B1 (en) | 2025-06-01 |
| EP4172145A4 (en) | 2024-08-21 |
| LT4172145T (lt) | 2026-07-27 |
| US20250129023A1 (en) | 2025-04-24 |
| CN115867533A (zh) | 2023-03-28 |
| MX2022016212A (es) | 2023-03-02 |
| KR20230028543A (ko) | 2023-02-28 |
| JP7864902B2 (ja) | 2026-05-25 |
| DK4172145T3 (da) | 2026-07-20 |
| US11292765B2 (en) | 2022-04-05 |
| EP4786000A2 (en) | 2026-08-05 |
| KR20250103811A (ko) | 2025-07-07 |
| FI4172145T3 (fi) | 2026-07-22 |
| JP2023531311A (ja) | 2023-07-21 |
| AU2021302692A1 (en) | 2023-01-19 |
| EP4172145B1 (en) | 2026-05-13 |
| PT4172145T (pt) | 2026-07-17 |
| US20250382267A1 (en) | 2025-12-18 |
| CN119285526A (zh) | 2025-01-10 |
| CA3181092A1 (en) | 2022-01-06 |
| WO2022000091A1 (en) | 2022-01-06 |
| US20220177427A1 (en) | 2022-06-09 |
| JP2025143280A (ja) | 2025-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115867533B (zh) | 色胺前药 | |
| CN118679146A (zh) | 色胺前药 | |
| US10676438B2 (en) | KCNQ2-5 channel activator | |
| EA007008B1 (ru) | Триамидзамещённые индолы, бензофураны и бензотиофены в качестве ингибиторов микросомального белка, переносящего триглицериды, (мтр) и/или ингибиторов секреции аполипопротеина в (аро в) | |
| WO2005016326A2 (en) | Analogs of thalidomide as potential angiogenesis inhibitors | |
| TW201021798A (en) | Amide acetate derivative having inhibitory activity on endothelial lipase | |
| WO1999020620A1 (en) | Isoquinoline derivative and drug | |
| WO2016159577A2 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
| WO2018133670A1 (zh) | 丁苯酞-替米沙坦杂合物及其制备方法和用途 | |
| JP4832897B2 (ja) | エステル誘導体及びその医薬用途 | |
| WO2019007382A1 (zh) | 吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用 | |
| CA3075324A1 (en) | Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof | |
| HK40114252A (en) | Tryptamine prodrugs | |
| HK40114605A (en) | Tryptamine prodrugs | |
| HK40091294A (en) | Tryptamine prodrugs | |
| HK40091294B (en) | Tryptamine prodrugs | |
| HK40114112A (zh) | 色胺前药 | |
| WO2004089411A1 (ja) | 脊柱管狭窄症治療剤 | |
| JP2021512958A (ja) | 神経変性疾患を治療するための医薬及びその使用 | |
| TW201102380A (en) | Novel heterocyclic compounds | |
| JPWO2013018685A1 (ja) | ラクタム誘導体及びその医薬用途 | |
| CN110256461A (zh) | 稠杂嘧啶衍生物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40114252 Country of ref document: HK |